Search alternatives:
associated decrease » associated increase (Expand Search), associated disease (Expand Search), associated diseases (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 7,096 for search '(( significant ((nn decrease) OR (fold decrease)) ) OR ( significantly associated decrease ))', query time: 0.61s Refine Results
  1. 1
    Log2 fold change (FC) of the overlaps of lipid metabolites between the study groups and those significant metabolites that appear exclusively in a single group (unique) represented in the Venn diagram.

    Log2 fold change (FC) of the overlaps of lipid metabolites between the study groups and those significant metabolites that appear exclusively in a single group (unique) represented... by Laia Bertran (3685147)

    Published 2025
    Save to List
    Saved in:
  2. 2
    EF-24 induces significant transcriptional changes in K-562 cells.

    EF-24 induces significant transcriptional changes in K-562 cells. by Ajeet P. Singh (22298432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort.

    Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort. by Yu Zhang (12946)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Summary of Biomarker Expression in Benign Samples. The STT and LTT groups exhibit significant changes in biomarker expression compared to the nontreatment group, measured on a two-fold logarithmic scale. STT: Short-term dihydrotestosterone treatment. LTT: Long-term dihydrotestosterone treatment.

    Summary of Biomarker Expression in Benign Samples. The STT and LTT groups exhibit significant changes in biomarker expression compared to the nontreatment group, measured on a two-... by Jinho Lee (587173)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Significant associations in GWAS.

    Significant associations in GWAS. by Dai Nogimura (21445649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Actin-Targeted Magnetic Nanomotors Mechanically Modulate the Tumor Mechanical Microenvironment for Cancer Treatment

    Actin-Targeted Magnetic Nanomotors Mechanically Modulate the Tumor Mechanical Microenvironment for Cancer Treatment by Xing Fan (88299)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.4), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.8), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Genes with highest fold change in exponential compared to stationary phase. Genes with >10 fold enrichment are shown, ribosomal genes are highlighted with bolded text. <i>rpsJ</i>/S10 is highlighted with a black box.

    Genes with highest fold change in exponential compared to stationary phase. Genes with >10 fold enrichment are shown, ribosomal genes are highlighted with bolded text. <i>rpsJ</i>/... by Justin Greene (306625)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Significant associations in the candidate gene approach.

    Significant associations in the candidate gene approach. by Dai Nogimura (21445649)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and heart rate (HR) across the three conditions.

    Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

    Published 2025
    Save to List
    Saved in:
  16. 16
    Kaplan-Meier curves and time-dependent Cox regression for outcome of mortality.

    Kaplan-Meier curves and time-dependent Cox regression for outcome of mortality. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 17
    Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE.

    Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    Adverse cardiovascular events by immune checkpoint inhibitor.

    Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 19
    Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events.

    Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 20
    Minimal dataset.

    Minimal dataset. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: